Reducing the supply of fibril precursors in systemic amyloidosis

Disease	Aim of treatment	Example of treatment
AA amyloidosis	Suppress the acute phase response and thereby reduce the production of serum amyloid A protein	Anti-inflammatory and immunosuppressive therapy in patients with rheumatoid arthritis and Crohn disease (eg, anti-TNF antibodies, humanized anti-IL6 receptor antibody) Colchicine for patients with familial Mediterranean fever Surgery for patients with osteomyelitis and rare cytokine-producing tumors
AL amyloidosis	Suppress production of monoclonal immunoglobulin light chains	Chemotherapy directed at plasma cell dyscrasia
Hereditary amyloidosis	Eliminate source of genetically variant protein	Orthotopic liver transplantation for patients with familial amyloid polyneuropathy secondary to variant transthyretin or renal amyloidosis secondary to variant fibrinogen A α-chain
β₂-microglobulin amyloidosis	Reduce plasma concentration of β₂-microglobulin	Renal transplantation

Adapted by permission from: Macmillan Publishers Ltd: Nature Clinical Practice Nephrology. Gillmore JD, Hawkins PN. Drug insight: Emerging therapies for amyloidosis. Nat Clin Pract Nephrol 2006; 2:263. Copyright © 2006. www.nature.com/nrneph.

Graphic 87769 Version 3.0

خرید پکیج

Reducing the supply of fibril precursors in systemic amyloidosis